KYMERA THERAPEUTICS, INC.— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$34M
↑+55.5% +$12Mvs FY2025 (Q4)
Gross Profit
$0
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $34M | $22M |
| COGS | $34M | $22M |
| Gross Profit | $0 | $0 |
| R&D | $98M | $80M |
| SG&A | $0 | $0 |
| D&A | $2M | $2M |
| Other OpEx | $15M | $9M |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · KYMR · Comparing FY2026 (Q4) vs FY2025 (Q4)